Pharnext to Launch New Phase 3 Trial of PXT3003 for CMT1A
Pharnext is planning a new Phase 3 clinical study to further explore the potential of PXT3003 in patients with Charcot-Marie-Tooth disease type 1A (CMT1A). The decision to launch this new clinical trial was based on recommendations given by the U.S. Food and Drug Administration (FDA) after completing…